The firms are developing the autologous CAR T-cell therapy IB-T101 as a treatment for clear cell renal cell carcinoma.

R-targeted therapy PMB-CT01 for treating B-cell malignancies, including heavily pretreated follicular lymphoma.

NEW YORK – The US Food and Drug Administration on Friday granted accelerated approval to Pfizer's Braftovi (encorafenib) plus Eli Lilly's Erbitux (cetuximab) with chemotherapy for patients with newly ...

The company separately said it has started treating patients within a Phase III trial testing an ASO drug for Angelman syndrome.

The program, aimed at reducing how much Americans spend on prescription drugs, includes several precision medicines.

The agency's decision not to approve this formulation was based on issues identified during a pre-approval inspection at a manufacturing facility, the firm said.

NEW YORK – 2024 was a banner year of "firsts" in the gene therapy space, as the US Food and Drug Administration greenlit ...

AI-driven tools for prescreening patients, predicting responses and outcomes, and guiding patient therapy are maturing and entering the market.

The firm plans to launch trials to study the agent in biomarker-defined cancer types, including breast and lung cancers.

Scipher will contribute data derived from its PrismRA blood test to the Atropos Evidence Network, which underpins software tools, including an AI chatbot.

The company is using its Senza5 platform to produce CAR T cells without the CD5 receptor, hoping to enable smaller doses and avoid CAR-T fratricide.

The firms have teamed up on a Phase I trial to evaluate the off-the-shelf cell therapy SN301A in patients with advanced GPC3-expressing liver cancers.